Philip K.
- Country
- Germany
- Department
- Klinik und Poliklinik für Strahlentherapie
Research Overview
- Evaluation of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Stage III Unresectable Non-Small Cell Lung Cancer Post-Platinum-Based Chemoradiation
- Evaluation of Durvalumab in Combination with Cisplatin, Carboplatin, and Etoposide with Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 2 of 55 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating extensive stage small cell lung cancer (SCLC), exploring innovative therapeutic approaches in thoracic oncology.
- Thoracic Malignancies
- Small Cell Lung Cancer
- Advanced Stage Cancer Treatment
Particular expertise in combined modality treatments for thoracic cancers.
Therapeutic Expertise
Shows dedication to developing integrated treatment approaches combining radiochemotherapy with immunotherapy interventions.
- Combination Therapy
- Radiotherapy Techniques
- Immunotherapeutic Approaches
Focus on optimizing treatment sequences in complex oncological cases.
Technical Specialization
Expert in advanced radiation delivery methods, particularly stereotactic radiotherapy and consolidative radiotherapy techniques.
- Precision Radiation Delivery
- Multimodal Treatment Integration
- Therapeutic Innovation
Specializes in implementing cutting-edge radiation treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.